Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Trauner, M; Halilbasic, E; Claudel, T; Steinacher, D; Fuchs, C; Moustafa, T; Pollheimer, M; Krones, E; Kienbacher, C; Traussnigg, S; Kazemi-Shirazi, L; Munda, P; Hofer, H; Fickert, P; Paumgartner, G.
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Dig Dis. 2015; 33(3):433-439
Doi: 10.1159/000371904
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Trauner Michael
- Co-Autor*innen der Med Uni Graz
- Claudel Thierry
- Fickert Peter
- Fuchs Claudia
- Halilbasic Emina
- Hofer Herwig
- Moustafa Tarek
- Pollheimer Marion
- Tatscher Elisabeth
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- 24-nor-ursodeoxycholic acid (norUDCA) is a side-chain shortened derivate of ursodeoxycholic acid (UDCA). Since norUDCA is only ineffectively conjugated with glycine or taurine, it has specific physicochemical and therapeutic properties distinct from UDCA. Nonamidated norUDCA undergoes cholehepatic shunting enabling 'ductular targeting' and inducing a bicarbonate-rich hypercholeresis, with cholangioprotective effects. At the same time it has direct anti-inflammatory, antilipotoxic, anti fibrotic, and antiproliferative properties targeting various liver cell populations. norUDCA appears to be one of the most promising novel treatment approaches targeting the liver and the bile duct system at multifactorial and multicellular levels. This review article is a summary of a lecture given at the XXIII International Bile Acid Meeting (Falk Symposium 194) on 'Bile Acids as Signal Integrators and Metabolic Modulators' held in Freiburg, October 8-9, 2014, and summarizes the recent progress with norUDCA as a novel therapeutic approach in cholestatic and metabolic (liver) disorders. 2015 S. Karger AG, Basel.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Bile Duct Diseases - drug therapy
- Humans -
- Liver Diseases - drug therapy
- Metabolic Diseases - drug therapy
- Signal Transduction - drug effects
- Ursodeoxycholic Acid - analogs & derivatives
- Ursodeoxycholic Acid - therapeutic use
- Find related publications in this database (Keywords)
- Primary sclerosing cholangitis
- Primary biliary cirrhosis
- Bicarbonate umbrella
- Nonalcoholic fatty liver disease
- Atherosclerosis